Metformin in adolescents
Pro Research Analysisby 
Searched over 200M research papers
Metformin for Obesity and Insulin Resistance in Adolescents
Effects on Body Mass Index (BMI) and Weight
Multiple studies show that metformin leads to modest but significant reductions in BMI and body weight in obese adolescents, especially when combined with lifestyle interventions such as diet and exercise. Randomized controlled trials and meta-analyses consistently report that metformin reduces BMI by about 1–1.4 kg/m² compared to placebo, and also decreases waist circumference and body fat percentage in this population 1367+2 MORE. These effects are generally observed over short- to medium-term treatment periods (6–18 months), with some evidence of BMI stabilization or modest improvement over longer periods 3567+2 MORE.
Insulin Sensitivity and Metabolic Improvements
Metformin improves insulin sensitivity and reduces insulin resistance in obese adolescents, as measured by the homeostasis model assessment (HOMA-IR) and oral glucose tolerance tests 1368+1 MORE. These improvements are associated with reductions in fasting glucose, plasma insulin, and other metabolic risk factors such as cholesterol, triglycerides, and leptin levels 1368. However, some long-term studies suggest that the benefits on insulin resistance may not be sustained with prolonged use, possibly due to compliance issues or insufficient dosing .
Use in Adolescents with Type 1 Diabetes
In adolescents with type 1 diabetes and poor metabolic control, adding metformin to insulin therapy can lower HbA1c levels and reduce daily insulin requirements without causing weight gain 249. Meta-analyses and systematic reviews confirm that metformin decreases HbA1c, BMI, and total daily insulin dose, but also increases the risk of mild hypoglycemia and gastrointestinal side effects 249. Improvements in insulin sensitivity are less consistently documented, and more research is needed to determine long-term benefits and optimal dosing 249.
Safety and Tolerability
Metformin is generally well tolerated in adolescents, with the most common side effects being mild gastrointestinal symptoms such as nausea and diarrhea 24910. The risk of severe adverse events is low, but there is a higher frequency of mild hypoglycemia when metformin is used alongside insulin in type 1 diabetes 249. Long-term safety data are limited, but available studies report no serious adverse events 3510.
Conclusion
Metformin offers modest but meaningful benefits for reducing BMI, body fat, and insulin resistance in obese adolescents, and can help improve metabolic control in those with type 1 diabetes. Its safety profile is generally acceptable, though gastrointestinal side effects and mild hypoglycemia (in type 1 diabetes) are more common. While metformin can be a useful adjunct to lifestyle interventions, especially for those not responding to lifestyle changes alone, longer-term studies are needed to clarify its sustained effects and optimal use in adolescent populations.
Sources and full results
Most relevant research papers on this topic